Safety and Efficacy of Cardiac Shockwave Therapy in Patients Undergoing Coronary Artery Bypass Grafting

NACompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

June 1, 2022

Study Completion Date

March 15, 2023

Conditions
Heart Failure PatientsCardiac Ischemia
Interventions
DEVICE

Shockwave Therapy

The cardiac shockwave system consists of a table-top device (Nonvasiv Medical GmbH, Konstanz, Germany) and a sterile single-use applicator releasing electrohydraulic shockwaves (Heart Regeneration Technologies GmbH, Innsbruck, Austria). Prior to use, the applicator is inserted into a sterile cover containing ultrasound gel. In order to ensure acoustic coupling between the applicator and the myocardium, continuous saline rinsing is applied throughout the procedure.

Trial Locations (1)

6020

Medical University of Innsbruck - Competence Center for Clinical Trials, Innsbruck

All Listed Sponsors
lead

Medical University Innsbruck

OTHER

NCT03859466 - Safety and Efficacy of Cardiac Shockwave Therapy in Patients Undergoing Coronary Artery Bypass Grafting | Biotech Hunter | Biotech Hunter